Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2018

  • ID: 4482723
  • Report
  • 217 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Aldeyra Therapeutics Inc
  • Huons Global Co Ltd
  • Merck & Co Inc
  • Ocular Therapeutix Inc
  • Pharmaleads SA
  • Seikagaku Corp
  • MORE
Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2018, provides an overview of the Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline landscape.

Keratoconjunctivitis sicca (KCS) or dry eye disease (DED) or dry eye syndrome (DES) is a condition in which a person experience desiccation of the conjunctiva and cornea due to an inadequate tear film. Symptoms include hyperemia, mucoid discharge, ocular irritation, photophobia and blurry vision. Risk factors include age, wearing contact lenses and low levels of vitamin A. Treatment includes artificial tear substitutes, topical anti-inflammatory agents, secretagogues and immunosuppressants.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Keratoconjunctivitis sicca (Dry Eye) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Keratoconjunctivitis sicca (Dry Eye) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 9, 20, 8, 30, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.

Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Keratoconjunctivitis sicca (Dry Eye) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aldeyra Therapeutics Inc
  • Huons Global Co Ltd
  • Merck & Co Inc
  • Ocular Therapeutix Inc
  • Pharmaleads SA
  • Seikagaku Corp
  • MORE
Introduction

Keratoconjunctivitis sicca (Dry Eye) - Overview

Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Development

Keratoconjunctivitis sicca (Dry Eye) - Therapeutics Assessment

Keratoconjunctivitis sicca (Dry Eye) - Companies Involved in Therapeutics Development

Keratoconjunctivitis sicca (Dry Eye) - Drug Profiles

Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects

Keratoconjunctivitis sicca (Dry Eye) - Discontinued Products

Keratoconjunctivitis sicca (Dry Eye) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Aldeyra Therapeutics Inc, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Allergan Plc, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ascendia Pharmaceuticals LLC, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Aurinia Pharmaceuticals Inc, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by BioLineRx Ltd, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Cambium Medical Technologies LLC, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Clementia Pharmaceuticals Inc, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Dompe Farmaceutici SpA, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by HanAll Biopharma Co Ltd, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Huons Global Co Ltd, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Icure Pharmaceutical Inc, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kala Pharmaceuticals Inc, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kukje Pharmaceutical Industry Co Ltd, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Kv1.3 Therapeutics, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Laboratoires Thea SA, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Merck & Co Inc, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Mitotech SA, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Nanomerics Ltd, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Nemus Bioscience Inc, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Novaliq GmbH, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ocular Therapeutix Inc, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Oculis ehf, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Ocunova LLC, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by OncoNOx ApS, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Otsuka Holdings Co Ltd, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Pharmaleads SA, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Quorum Innovations LLC, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Realm Therapeutics Plc, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Redwood Pharma AB, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Samjin Pharm Co Ltd, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Santen Pharmaceutical Co Ltd, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Seikagaku Corp, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Shire Plc, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Sylentis SAU, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TearSolutions LLC, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by TopiVert Ltd, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Vanda Pharmaceuticals Inc, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Pipeline by Xigen SA, H1 2018

Keratoconjunctivitis sicca (Dry Eye) - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Keratoconjunctivitis sicca (Dry Eye), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aldeyra Therapeutics Inc
  • Allergan Plc
  • Ascendia Pharmaceuticals LLC
  • Aurinia Pharmaceuticals Inc
  • BioLineRx Ltd
  • Cambium Medical Technologies LLC
  • Chong Kun Dang Pharmaceutical Corp
  • Clementia Pharmaceuticals Inc
  • Dompe Farmaceutici SpA
  • HanAll Biopharma Co Ltd
  • Huons Global Co Ltd
  • Icure Pharmaceutical Inc
  • Kala Pharmaceuticals Inc
  • Kukje Pharmaceutical Industry Co Ltd
  • Kv1.3 Therapeutics
  • Laboratoires Thea SA
  • Merck & Co Inc
  • Mitotech SA
  • Nanomerics Ltd
  • Nemus Bioscience Inc
  • Novaliq GmbH
  • Ocular Therapeutix Inc
  • Oculis ehf
  • Ocunova LLC
  • OncoNOx ApS
  • Otsuka Holdings Co Ltd
  • Pharmaleads SA
  • Quorum Innovations LLC
  • Realm Therapeutics Plc
  • Redwood Pharma AB
  • RegeneRx Biopharmaceuticals Inc
  • Samjin Pharm Co Ltd
  • Santen Pharmaceutical Co Ltd
  • Seikagaku Corp
  • Shire Plc
  • Sun Pharma Advanced Research Company Ltd
  • Sylentis SAU
  • TearSolutions LLC
  • TopiVert Ltd
  • Vanda Pharmaceuticals Inc
  • Xigen SA
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll